Wednesday, October 27, 2021 5:00:50 PM
About a year and a half ago, Joanne Fagg published an article "Rett failure sets up thin pipeline" on evaluate.com.
She showed the status of four companies with Rett p3 trials and their status.
Pharma is a difficult business and two companies have since stopped their Rett trials.
Anavex and Acadia's Trofinetide are still continuing. Acadia's trial is for children, and should be finishing up now, as well as Anavex's Avatar adult study. Unfortunately, the Excellence-pediatric study has slipped AT LEAST well into next year. At least a year later than the article's table above shows. Competitively, schedules do matter!
Anavex's A2-73 has been shown to be superior, per analysis shown here and per Dr.Misslings corporate presentation:
Recent AVXL News
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
